API
< Back to all clusters
[BUSINESS] · Brazil · 6 sources

started · updated

GLP-1 weight loss drug prescriptions surge 304.9% in Brazil

Digital prescriptions for GLP-1 weight loss medications in Brazil surged by 304.9% in 2025 compared to the previous year, according to data from Memed. This marks the third consecutive year of significant growth for the category, which is estimated to generate R$ 3.8 billion per quarter in the pharmaceutical retail sector.

The market share for specific brands has shifted significantly. While Ozempic held a dominant position in 2022 and 2023, its share of digital prescriptions dropped to 9% in 2025 and 4% in the first half of 2026. Conversely, Mounjaro (tirzepatide) has taken a leading role, capturing 44% of emissions in 2025 and reaching 58% in the first half of 2026. Wegovy holds a 20% market share, while Rybelsus accounts for 7%.

In the retail sector, the average price of GLP-1 pens has begun to decline following the expiration of the semaglutide patent. Analysts from XP Investimentos report that while sales volumes are increasing, the drop in average prices has led to a slight decrease in revenue for certain indicators. The market is transitioning from a focus on revenue to a competition based on volume and margins as similar products like Ozivy (EMS) and Semavy (Hypera) enter the market.

Entities

Anvisa · Hypera · XP Investimentos